CTRI/2022/12/048330尚未招募4 期
Oral JAK Inhibitor Tofacitinib In Enthesitis Related Arthritis Variant Of Juvenile Idiopathic Arthritis: A Single Center Double Blinded Randomized Control Study
Sanjay Gandhi Postgraduate Institute off Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Children with JIA-ERA with total disease duration <5 years and who are above 5 years and below 18 years of age with BASDAI >4 and elevated ESR >30 or CRP >6 mg/L while on NSAIDS and Methotrexate for at least 3 months.
排除标准
- •Those with active TB/infections, transaminitis ( >3 times ULN), any organ damage, cancer, <5 years of age, inactive disease.
研究者
相似试验
进行中（未招募）
1 期
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's SyndromeSjogren's SyndromeNCT04496960National Institute of Dental and Craniofacial Research (NIDCR)23
进行中（未招募）
1 期
The effect of the new anti-rheumatic drug tofacitinib on cytokine-induced inflammatory pathways in patients with rheumatoid arthritisRheumatoid arthritisEUCTR2017-002753-11-FITampere University Hospital24
尚未招募
3 期
Effect of Tofacitinib enema in improving disease activity in Ulcerative ColitisCTRI/2024/08/071795All India Institute of Medical Sciences New Delhi Delhi
进行中（未招募）
1 期
Efficacy of Tofacitinib in Reduction of Spinal Inflammation Detected on MRI in Patients with Psoriatic ArthritiSPsoriatic Arthritis with axial (spinal) involvementMedDRA version: 21.0Level: LLTClassification code 10037166Term: Psoriatic spondylitisSystem Organ Class: 100000004859MedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2018-004254-22-DECharite University80
尚未招募
Unknown
A comparison of efficacy and safety of oral tofacitinib vs methotrexate in management of moderate to severe chronic plaque psoriasisCTRI/2023/06/053443one